Pan-immune-inflammatory value in patients with hyperuricemia: a population-based study

The pan-immune-inflammation value (PIV) is a promising biomarker that reflects systemic inflammation and aids in disease prognosis. We sought to explore the potential association between PIV and hyperuricemia in the adult population of the USA.

The data were collected from the National Health and Nutrition Examination Survey (NHANES) 2007-2018. PIV was calculated as follows: (neutrophil × platelet × monocyte)/lymphocyte (10⁹/L). Hyperuricemia is defined as uric acid levels ≥ 420 mmol/L in males and ≥ 360 mmol/Ls in females. The association between PIV and the prevalence of hyperuricemia, as well as its impact on all-cause and cardiovascular mortality, was investigated.

A total of 31,151 adult participants were included in this study. The prevalence of hyperuricemia increased progressively with higher PIV levels (13.41% vs. 14.87% vs. 15.75% vs. 20.02%, P < 0.001). Participants in the fourth quartile of PIV had a greater risk of hyperuricemia compared to those in the first quartile (OR = 1.19, 95% CI: 1.07-1.32, P = 0.001). Smooth curve fitting also indicated a dose-response relationship between PIV levels and hyperuricemia risk. Additionally, elevated PIV levels were linked to an increased risk of all-cause and cardiovascular mortality in patients with hyperuricemia (P < 0.001).

PIV is an emerging biomarker reflecting systemic inflammation, with the potential for assessing hyperuricemia and its prognostic risk. Key Points • Pan-immune-inflammation value (PIV) holds potential as an epidemiological tool for analyzing immune-inflammatory responses tied to hyperuricemia and its long-term mortality risk.